Novo Nordisk A/S (NVO) closed at $40.70 on November 17, 2026, down 2.2% from the previous close, on volume of 14,171,012 shares (30-day average 11,304,040).
Data as of November 17, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 19, 2026 | Ratio Put Spread 1 by 2 | 20-Nov-2635[2x] : 38 P | 35,400 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
PRNewswire (Tue, 17-Nov 8:00 AM ET)
Novo Nordisk Details Share Repurchases Through November 13
TipRanks (Mon, 16-Nov 12:19 PM ET)
Biggest stock movers Monday: Crypto stocks, INTC, TU, and more
Seeking Alpha News (Mon, 16-Nov 10:32 AM ET)
Biggest stock movers Monday: Crypto stocks, INTC, and more
Seeking Alpha News (Mon, 16-Nov 5:01 AM ET)
Lilly’s Zepbound shows promise in teen obesity trial
Seeking Alpha News (Sun, 15-Nov 6:38 PM ET)
Novo Nordisk reports additional CagriSema weight-loss findings
Seeking Alpha News (Sun, 15-Nov 3:09 PM ET)
SA Asks: What are the most attractive Big Pharma stocks right now?
Seeking Alpha News (Sun, 15-Nov 2:56 PM ET)
The Week That Was, The Week Ahead: Macro and Markets, November 15
TipRanks (Sun, 15-Nov 4:14 AM ET)
Novo Nordisk Earnings Call Signals Recovery Amid Headwinds
TipRanks (Sat, 14-Nov 11:42 PM ET)
GLP-1s can save health system money if priced below $350 a month: analysis
Seeking Alpha News (Sat, 14-Nov 5:26 PM ET)
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Novo Nordisk A/S trades on the NYSE stock market under the symbol NVO.
As of November 18, 2026, NVO stock price declined to $39.65 with 5,981,746 million shares trading.
NVO has a beta of 0.79, meaning it tends to be less sensitive to market movements. NVO has a correlation of 0.05 to the broad based SPY ETF.
NVO has a market cap of $174.75 billion. This is considered a Large Cap stock.
Last quarter Novo Nordisk A/S reported $12 billion in Revenue and $.89 earnings per share. This beat revenue expectation by $802 million and exceeded earnings estimates by $.08.
In the last 3 years, NVO traded as high as $148.15 and as low as $35.12.
The top ETF exchange traded funds that NVO belongs to (by Net Assets): AVDE, PPH, WCMI, FENI, PID.
NVO has underperformed the market in the last year with a return of -14.4%, while the SPY ETF gained +10.9%. In the last 3 month period, NVO fell short of the market, returning -11.7%, while SPY returned -5.2%. However, in the most recent 2 weeks NVO has outperformed the stock market by returning -1.3%, while SPY returned -3.1%.
NVO support price is $40.09 and resistance is $41.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVO shares will trade within this expected range on the day.